Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States

Abstract

G4/5 patients with asthma incurred significantly greater direct and indirect costs than non-G4/5 patients with asthma. Differences were largely driven by those with Ex/R.